Sfoglia per Autore
Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.)
2007-01-01 Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; Petrini, Iacopo; Barletta, M. T.; Baldi, G. G.; Falcone, Alfredo
Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line folfoxiri followed by r0 surgical resection of metastases
2007-01-01 Masi, G.; Bursi, S.; Loupakis, F.; Barletta, M.; Barbara, C.; Vasile, E.; Cupini, S.; Brunetti, I.; Pfanner, E.; DI DONATO, S.; Dauria, G.; Fanchini, L.; Chiara, S.; Granetto, C.; Falcone, Alfredo
Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases
2007-01-01 Masi, G.; Bursi, S.; Loupakis, F.; Barbara, C.; Brunetti, I.; Ferraldeschi, R.; Evangelista, W.; Chiara, S.; Granetto, C.; Falcone, Alfredo
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report
2007-01-01 Barletta, M. T.; Bocci, Guido; Loupakis, F.; Fioravanti, A.; Baldi, G.; Orlandi, P.; Allegrini, G.; Masi, G.; Barbara, C.; Andreuccetti, M.; Cupini, S.; Bursi, S.; Danesi, Romano; DI PAOLO, Antonello; DEL TACCA, M.; Falcone, Alfredo
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
2007-01-01 Ruzzo, Annamaria; Graziano, Francesco; Loupakis, Fotios; Rulli, Eliana; Canestrari, Emanuele; Santini, Daniele; Catalano, Vincenzo; Ficarelli, Rita; Maltese, Paolo; Bisonni, Renato; Masi, Gianluca; Schiavon, Gaia; Giordani, Paolo; Giustini, Lucio; Falcone, Alfredo; Tonini, Giuseppe; Silva, Rosarita; Mattioli, Rodolfo; Floriani, Irene; Magnani, Mauro
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
2008-01-01 Allegrini, G.; Bocci, Guido; Barletta, M.; Fioravanti, A.; DI DESIDERIO, T.; Loupakis, F.; Masi, G.; Baldi, G.; DI MARSICO, R.; DEL TACCA, M.; DI LEO, A.; Brandi, G.; Andreuccetti, M.; Kerbel, R.; Falcone, Alfredo
Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
2008-01-01 Allegrini, G.; Bocci, Guido; Barletta, M. T.; Masi, G.; Loupakis, F.; Fioravanti, A.; Desidero, T.; Andreuccetti, M.; DI LEO, A.; Falcone, Alfredo
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach
2008-01-01 Loupakis, F.; Vasile, E.; Santini, D.; Masi, G.; Falcone, Alfredo; Graziano, F.
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
2008-01-01 Graziano, F.; Ruzzo, A.; Loupakis, F.; Santini, D.; Catalano, V.; Canestrari, E.; Maltese, P.; Bisonni, R.; Fornaro, L.; Baldi, G.; Masi, G.; Falcone, Alfredo; Tonini, G.; Giordani, P.; Alessandrini, P.; Giustini, L.; Vincenti, B.; Magnani, M.
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer
2008-01-01 Masi, G.; Vasile, E.; Loupakis, F.; Bursi, S.; Ricci, S.; Petrini, Iacopo; Fontana, A.; Allegrini, G.; Falcone, Alfredo
Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment
2008-01-01 Irene, Stasi; Fotios, Loupakis; Luca, Pollina; Masi, Gianluca; Nicola, Funel; Mario, Scartozzi; Petrini, Iacopo; Daniele, Santini; Stefano, Cascinu; Falcone, Alfredo
K-RAS status in primary colorectal tumours correlate with K-RAS status in related metastatic sites: implications for treatment with anti-EGFR antibodies in clinical setting
2008-01-01 Santini, D.; Loupakis, F.; Vincenzi, B.; Perrone, G.; Graziano, F.; Floriani, I.; Maltese, P.; Stasi, I.; Canestrari, E.; Masi, G.; ONETTI MUDA, A.; Magnani, M.; Falcone, Alfredo; Ruzzo, A.; Tonini, G.
Phase II study of irinotecan, oxaliplatin and infusional 5FU/LV (GONO-FOLFOXIRI) plus bevacizumab (BV) as first-line treatment in metastatic colorectal cancer (MCRC)
2008-01-01 Masi, G.; Loupakis, F.; Vasile, E.; Cupini, S.; Fornaro, L.; Baldi, G. G.; Stasi, I.; Salvatore, L.; Ciarlo, A.; Cavaciocchi, D.; Ciprotti, M.; Puglisi, M.; Rondini, M.; Puccinelli, P.; Granetto, C.; DI DONATO, S.; Antonuzzo, A.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo
Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment
2008-01-01 Loupakis, F.; Stasi, I.; Pollina, L.; Masi, G.; Baldi, G.; Fornaio, L.; Schiavon, G.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Funel, N.; Campani, Daniela; Tonini, G.; Cascinu, S.; Falcone, Alfredo
Phase II study of first-line treatment in metastatic colorectal cancer (MCRC) with GONO-FOLFOXIRI (Irinotecan, Oxaliplatin and Infusional 5FU/LV) plus Bevacizumab
2008-01-01 Masi, G.; Loupakis, F.; Vasile, E.; Ciarlo, A.; Cavaciocchi, D.; Ciprotti, M.; Donati, S.; Fea, E.; DI DONATO, S.; Falcone, Alfredo
First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?
2008-01-01 Loupakis, F.; Masi, G.; Vasile, E.; Falcone, Alfredo
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction
2008-01-01 Bocci, Guido; DI PAOLO, Antonello; Masi, G.; Fornaro, L.; Allegrini, G.; Falcone, Alfredo; DEL TACCA, M.; Danesi, Romano
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS)
2008-01-01 Loupakis, F.; Stasi, I.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Funel, N.; Fornaro, L.; Baldi, G. G.; Salvatore, L.; Cupini, S.; Petrini, Iacopo; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Ricci, S.; Tonini, G.; Magnani, M.; Falcone, Alfredo
Insulin-like growth factor-1 (IGF-1) correlates with clinical outcome in metastatic colorectal patients treated with irinotecan/cetuximab combination
2008-01-01 Pierantoni, C.; Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Loupakis, F.; Masi, G.; Berardi, R.; Zaniboni, A.; Quadri, A.; Zorzi, F.; Biscotti, T.; Labianca, R.; Falcone, Alfredo; Cascinu, S.
Chemotherapy without monoclonal antibodies in the treatment of metastatic colorectal cancer: Role of Triplets
2008-01-01 Falcone, Alfredo; Loupakis, F.; Vasile, E.; Masi, G.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Capecitabine ( C ), in combination with irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) | 1-gen-2007 | Bursi, S.; Masi, G.; Loupakis, F.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; Petrini, Iacopo; Barletta, M. T.; Baldi, G. G.; Falcone, Alfredo | |
| Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line folfoxiri followed by r0 surgical resection of metastases | 1-gen-2007 | Masi, G.; Bursi, S.; Loupakis, F.; Barletta, M.; Barbara, C.; Vasile, E.; Cupini, S.; Brunetti, I.; Pfanner, E.; DI DONATO, S.; Dauria, G.; Fanchini, L.; Chiara, S.; Granetto, C.; Falcone, Alfredo | |
| Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases | 1-gen-2007 | Masi, G.; Bursi, S.; Loupakis, F.; Barbara, C.; Brunetti, I.; Ferraldeschi, R.; Evangelista, W.; Chiara, S.; Granetto, C.; Falcone, Alfredo | |
| Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report | 1-gen-2007 | Barletta, M. T.; Bocci, Guido; Loupakis, F.; Fioravanti, A.; Baldi, G.; Orlandi, P.; Allegrini, G.; Masi, G.; Barbara, C.; Andreuccetti, M.; Cupini, S.; Bursi, S.; Danesi, Romano; DI PAOLO, Antonello; DEL TACCA, M.; Falcone, Alfredo | |
| Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy | 1-gen-2007 | Ruzzo, Annamaria; Graziano, Francesco; Loupakis, Fotios; Rulli, Eliana; Canestrari, Emanuele; Santini, Daniele; Catalano, Vincenzo; Ficarelli, Rita; Maltese, Paolo; Bisonni, Renato; Masi, Gianluca; Schiavon, Gaia; Giordani, Paolo; Giustini, Lucio; Falcone, Alfredo; Tonini, Giuseppe; Silva, Rosarita; Mattioli, Rodolfo; Floriani, Irene; Magnani, Mauro | |
| Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations | 1-gen-2008 | Allegrini, G.; Bocci, Guido; Barletta, M.; Fioravanti, A.; DI DESIDERIO, T.; Loupakis, F.; Masi, G.; Baldi, G.; DI MARSICO, R.; DEL TACCA, M.; DI LEO, A.; Brandi, G.; Andreuccetti, M.; Kerbel, R.; Falcone, Alfredo | |
| Metronomic chemotherapy (MC) with oral Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations | 1-gen-2008 | Allegrini, G.; Bocci, Guido; Barletta, M. T.; Masi, G.; Loupakis, F.; Fioravanti, A.; Desidero, T.; Andreuccetti, M.; DI LEO, A.; Falcone, Alfredo | |
| EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach | 1-gen-2008 | Loupakis, F.; Vasile, E.; Santini, D.; Masi, G.; Falcone, Alfredo; Graziano, F. | |
| Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy | 1-gen-2008 | Graziano, F.; Ruzzo, A.; Loupakis, F.; Santini, D.; Catalano, V.; Canestrari, E.; Maltese, P.; Bisonni, R.; Fornaro, L.; Baldi, G.; Masi, G.; Falcone, Alfredo; Tonini, G.; Giordani, P.; Alessandrini, P.; Giustini, L.; Vincenti, B.; Magnani, M. | |
| Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer | 1-gen-2008 | Masi, G.; Vasile, E.; Loupakis, F.; Bursi, S.; Ricci, S.; Petrini, Iacopo; Fontana, A.; Allegrini, G.; Falcone, Alfredo | |
| Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment | 1-gen-2008 | Irene, Stasi; Fotios, Loupakis; Luca, Pollina; Masi, Gianluca; Nicola, Funel; Mario, Scartozzi; Petrini, Iacopo; Daniele, Santini; Stefano, Cascinu; Falcone, Alfredo | |
| K-RAS status in primary colorectal tumours correlate with K-RAS status in related metastatic sites: implications for treatment with anti-EGFR antibodies in clinical setting | 1-gen-2008 | Santini, D.; Loupakis, F.; Vincenzi, B.; Perrone, G.; Graziano, F.; Floriani, I.; Maltese, P.; Stasi, I.; Canestrari, E.; Masi, G.; ONETTI MUDA, A.; Magnani, M.; Falcone, Alfredo; Ruzzo, A.; Tonini, G. | |
| Phase II study of irinotecan, oxaliplatin and infusional 5FU/LV (GONO-FOLFOXIRI) plus bevacizumab (BV) as first-line treatment in metastatic colorectal cancer (MCRC) | 1-gen-2008 | Masi, G.; Loupakis, F.; Vasile, E.; Cupini, S.; Fornaro, L.; Baldi, G. G.; Stasi, I.; Salvatore, L.; Ciarlo, A.; Cavaciocchi, D.; Ciprotti, M.; Puglisi, M.; Rondini, M.; Puccinelli, P.; Granetto, C.; DI DONATO, S.; Antonuzzo, A.; DI MARSICO, R.; Andreuccetti, M.; Falcone, Alfredo | |
| Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment | 1-gen-2008 | Loupakis, F.; Stasi, I.; Pollina, L.; Masi, G.; Baldi, G.; Fornaio, L.; Schiavon, G.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Funel, N.; Campani, Daniela; Tonini, G.; Cascinu, S.; Falcone, Alfredo | |
| Phase II study of first-line treatment in metastatic colorectal cancer (MCRC) with GONO-FOLFOXIRI (Irinotecan, Oxaliplatin and Infusional 5FU/LV) plus Bevacizumab | 1-gen-2008 | Masi, G.; Loupakis, F.; Vasile, E.; Ciarlo, A.; Cavaciocchi, D.; Ciprotti, M.; Donati, S.; Fea, E.; DI DONATO, S.; Falcone, Alfredo | |
| First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first? | 1-gen-2008 | Loupakis, F.; Masi, G.; Vasile, E.; Falcone, Alfredo | |
| Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction | 1-gen-2008 | Bocci, Guido; DI PAOLO, Antonello; Masi, G.; Fornaro, L.; Allegrini, G.; Falcone, Alfredo; DEL TACCA, M.; Danesi, Romano | |
| Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) | 1-gen-2008 | Loupakis, F.; Stasi, I.; Pollina, L.; Ruzzo, A.; Masi, G.; Cremolini, Chiara; Funel, N.; Fornaro, L.; Baldi, G. G.; Salvatore, L.; Cupini, S.; Petrini, Iacopo; Scartozzi, M.; Floriani, I.; Santini, D.; Cascinu, S.; Ricci, S.; Tonini, G.; Magnani, M.; Falcone, Alfredo | |
| Insulin-like growth factor-1 (IGF-1) correlates with clinical outcome in metastatic colorectal patients treated with irinotecan/cetuximab combination | 1-gen-2008 | Pierantoni, C.; Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Loupakis, F.; Masi, G.; Berardi, R.; Zaniboni, A.; Quadri, A.; Zorzi, F.; Biscotti, T.; Labianca, R.; Falcone, Alfredo; Cascinu, S. | |
| Chemotherapy without monoclonal antibodies in the treatment of metastatic colorectal cancer: Role of Triplets | 1-gen-2008 | Falcone, Alfredo; Loupakis, F.; Vasile, E.; Masi, G. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile